U.S. Markets open in 7 hrs 47 mins
  • S&P Futures

    4,357.75
    +8.75 (+0.20%)
     
  • Dow Futures

    34,219.00
    +34.00 (+0.10%)
     
  • Nasdaq Futures

    14,229.75
    +89.00 (+0.63%)
     
  • Russell 2000 Futures

    2,001.40
    +0.10 (+0.00%)
     
  • Crude Oil

    85.40
    -0.20 (-0.23%)
     
  • Gold

    1,847.70
    -4.80 (-0.26%)
     
  • Silver

    23.76
    -0.14 (-0.57%)
     
  • EUR/USD

    1.1307
    +0.0001 (+0.0113%)
     
  • 10-Yr Bond

    1.7830
    0.0000 (0.00%)
     
  • Vix

    31.16
    +2.31 (+8.01%)
     
  • GBP/USD

    1.3507
    +0.0001 (+0.0108%)
     
  • USD/JPY

    113.9260
    +0.0600 (+0.0527%)
     
  • BTC-USD

    37,442.27
    +1,393.92 (+3.87%)
     
  • CMC Crypto 200

    849.87
    +39.27 (+4.84%)
     
  • FTSE 100

    7,371.46
    -122.67 (-1.64%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MLLCF
  • MOLN

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Nov 30, 2021, at 8:00 AM EST.

The webcasted presentation will be made available on the Molecular Partners website.

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs

CONTACT: For further details, please contact: Seth Lewis seth.lewis@molecularpartners.com Tel: +1 781 420 2361 Shai Biran, Ph.D. shai.biran@molecularpartners.com Tel: +1 978 254 6286 Thomas Schneckenburger, European IR & Media thomas.schneckenburger@molecularpartners.com Tel: +41 79 407 9952